The patients were identified through electronic health records and other clinical decision support tools, which helped detect patients at risk of a venous or arterial thrombosis event. “The PREVENT-HD trial is a good model for how future outpatient clinical trials can be designed, harnessing patient data and embracing technology.”įrom August 2020 to April 2022, more than 1,280 diverse, COVID-19-positive, symptomatic patients were virtually consented and enrolled in the trial. Spyropoulos, MD, study co-principal investigator, professor at the Feinstein Institutes’ Institute of Health System Science and director of anticoagulation and clinical thrombosis services at Northwell Health.

“Since the start of the pandemic, we have been studying COVID-19, its risk to increase blood clots and the best course of treatment, both in and out of the hospital,” said Alex C. While the PREVENT-HD multi-center site clinical trial found no significant impact of rivaroxaban to prevent clots, the findings - along with its novel remote trial design -were published today in the journal Circulation. MANHASSET, N.Y.-( BUSINESS WIRE)-Because millions of people experience fatal venous and arterial thrombosis – blood clots – per year and those with COVID-19 are at higher risk, researchers at The Feinstein Institutes for Medical Research helped to design and implement an entirely virtual, outpatient, cloud-based clinical trial to understand the efficacy of a common prophylactic medication: rivaroxaban.

Download blood and dragon